Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        901-912 of 3963 results for 'Professor'

        Refine research

        Research

        Early life arsenic exposure and acute and long-term responses to influenza A infection in mice

        Exposure to arsenic in early life has been shown to increase the rate of respiratory infections during infancy, reduce childhood lung function, and increase... ...

        Research

        Factors influencing the assessment of lung function in mice with influenza-induced lung disease

        The constant-phase model (CPM) is commonly fit to respiratory system input impedance (Z rs) to estimate lung mechanics. ...

        Research

        Integrate, Identify, Intervene (Triple I Project): Identifying opportunities for preventing respiratory infections in children through integrating population-based health and laboratory data

        Christopher Hannah Blyth Moore CC HC MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and ...

        Research

        The Changing Detection Rate of Respiratory Syncytial Virus in Adults in Western Australia between 2017 and 2023

        The incidence of respiratory syncytial virus (RSV) in adults is inadequately defined and the impact of SARS-CoV-2-related non-pharmaceutical interventions (NPIs) is underexplored. Using laboratory data, we described the detection rate of RSV in adults ≥16 years in Western Australia (WA) between 2017 and 2023. ...

        Research

        COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement

        The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19. ...

        Research

        Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

        Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain. ...

        Research

        Global Prevalence of Varicella-Associated Complications: A Systematic Review and Meta-Analysis

        Varicella (chickenpox) is an infectious disease caused by the varicella zoster virus affecting children, adolescents, and adults. Varicella symptoms are usually self-limiting; however, different complications with widespread and systemic manifestations can occur. This systematic literature review aims to explore and quantify varicella-associated complication rates. ...

        Research

        Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

        A range of safe and effective vaccines against SARS CoV 2 are needed to address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 vaccine SCB-2019. ...

        Research

        Altered lung structure and function in mid-childhood survivors of very preterm birth

        To obtain comprehensive data on lung structure and function in mid-childhood from survivors of preterm birth. ...

        Research

        Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule

        The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule. ...

        Research

        Response after one dose of monovalent influenza A (H1n1) 2009 vaccine in infants and children - preliminary report

        To assess the immunogenicity and safety of a 2009 influenza A(H1N1) vaccine in children. ...

        Research

        A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR

        This study evaluated GSK's combined DTPa-IPV vaccine (Infanrix-IPV) given as a fifth consecutive acellular pertussis booster dose in conjunction... ...

        Page 76 of 331